Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
CVAC
CureVac N.V.
CureVac's core focus is oncology immunotherapies and cancer vaccines built on its mRNA platform (Biotech - Oncology).
|
$1.05B |
$4.66
|
|
ORIC
ORIC Pharmaceuticals, Inc.
ORIC develops oncology therapies (e.g., ORIC-944, ORIC-114, ORIC-533) targeting cancer resistance, placing it in Biotech - Oncology.
|
$1.05B |
$10.75
+5.08%
|
|
TIC
TIC Solutions, Inc.
Laboratory Testing & Advisory Services aligns with Acuren's lab-based destructive testing capabilities and analytical advisory work.
|
$1.04B |
$8.51
+6.51%
|
|
KALV
KalVista Pharmaceuticals, Inc.
EKTERLY (sebetralstat) is KalVista's lead asset and is an oral small-molecule therapeutic for acute hereditary angioedema, directly reflecting their product category.
|
$1.04B |
$20.50
+4.78%
|
|
BLFS
BioLife Solutions, Inc.
Sells consumables such as hPL, CellSeal vials, and CryoCase used within CGT workflows.
|
$1.04B |
$21.50
+3.12%
|
|
TDOC
Teladoc Health, Inc.
Integrated Care delivers virtual medical, mental health, and chronic condition management services.
|
$1.01B |
$5.70
-2.06%
|
|
SVRA
Savara Inc.
Molgramostim is a recombinant GM-CSF protein delivered as an inhalation therapy; directly a recombinant protein/enzymes product.
|
$1.00B |
$5.58
-3.79%
|
|
VTYX
Ventyx Biosciences, Inc.
VTX assets are oral small molecule therapeutics for autoimmune/inflammatory diseases (NLRP3 inhibitors).
|
$998.32M |
$14.00
|
|
VERV
Verve Therapeutics, Inc.
Verve Therapeutics' core offering is in vivo gene therapy using base editing delivered to liver cells, aligning with Biotech - Gene Therapy.
|
$988.30M |
$11.13
|
|
RAPT
RAPT Therapeutics, Inc.
RAPT's pipeline includes oncology-focused assets under Biotech - Oncology (tivumecirnon) and broader oncology immunotherapy focus.
|
$959.52M |
$57.99
-0.04%
|
|
FTRE
Fortrea Holdings Inc.
Fortrea operates as a standalone contract research organization providing outsourced clinical development services.
|
$959.11M |
$10.38
+2.82%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$958.91M |
$13.94
-1.10%
|
|
OPK
OPKO Health, Inc.
OPKO's BioReference segment provides laboratory testing and advisory services.
|
$951.95M |
$1.23
+1.65%
|
|
JANX
Janux Therapeutics, Inc.
Company focuses on tumor-activated oncology therapies (TRACTr/TRACIr), placing JANX squarely in Biotech - Oncology.
|
$951.54M |
$15.81
+4.08%
|
|
SSII
SS Innovations International, Inc.
Core product: robotic surgical system and endo-surgical instruments (SSi Mantra and related tools) sold as surgical equipment.
|
$946.81M |
$4.92
-0.20%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
VOQUEZNA (vonoprazan) is an oral small-molecule therapeutic (P-CAB) with GERD and H. pylori indications, representing the company’s core product line.
|
$938.32M |
$13.19
+4.56%
|
|
SANA
Sana Biotechnology, Inc.
Sana's lead platform is HIP-modified cell therapy (ex vivo) for allogeneic cell transplantation.
|
$937.61M |
$3.52
+1.30%
|
|
XNCR
Xencor, Inc.
Company develops and advances bispecific antibodies (XmAb 2+1 formats) for oncology and autoimmune indications.
|
$932.62M |
$13.05
+4.82%
|
|
INMD
InMode Ltd.
InMode's core business is medical devices and biometrics, with RF-based aesthetic platforms and related systems.
|
$926.64M |
$14.65
+2.23%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$919.51M |
$4.16
-3.03%
|
|
SDGR
Schrödinger, Inc.
The company operates a proprietary drug discovery pipeline with programs in oncology, aligning with Biotech - Oncology.
|
$909.02M |
$12.36
+2.49%
|
|
THRM
Gentherm Incorporated
Medical devices & biometrics including patient temperature management devices.
|
$908.73M |
$29.76
+4.57%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$907.77M |
$4.71
+0.75%
|
|
CGEM
Cullinan Therapeutics, Inc.
Cullinan develops bispecific antibodies (CD19xCD3 and BCMAxCD3) as core assets.
|
$889.69M |
$15.03
+1.97%
|
|
TBPH
Theravance Biopharma, Inc.
Ampreloxetine is an oral small-molecule therapeutic in Phase 3 (CYPRESS) for symptomatic nOH in MSA, representing a core TBPH pipeline asset.
|
$873.09M |
$17.23
+2.68%
|
|
BVS
Bioventus Inc.
Bioventus designs and manufactures medical devices and biometrics solutions for musculoskeletal health.
|
$870.67M |
$10.51
+0.96%
|
|
IART
Integra LifeSciences Holdings Corporation
Direct neurosurgery devices and surgical implants (e.g., CerebroFlo EVD catheter, Aurora Surgiscope) are core products.
|
$867.72M |
$11.14
+2.77%
|
|
MRVI
Maravai LifeSciences Holdings, Inc.
Maravai produces highly modified nucleic acids (mRNA, oligonucleotides) and related inputs, including acquisitions expanding DNA/RNA production capabilities.
|
$866.85M |
$3.39
-0.59%
|
|
QDEL
QuidelOrtho Corporation
The company monetizes high-margin medical device consumables and has a reagent rental/recurring revenue model.
|
$863.41M |
$12.69
|
Showing page 15 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
